IRadimed (IRMD) Stock Forecast, Price Target & Predictions
IRMD Stock Forecast
IRadimed stock forecast is as follows: an average price target of $60.00 (represents a 21.56% upside from IRMD’s last price of $49.36) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
IRMD Price Target
The average price target for IRadimed (IRMD) is $60.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential 21.56% upside from IRMD's last price of $49.36.
IRMD Analyst Ratings
According to 1 Wall Street analysts, IRadimed's rating consensus is 'Buy'. The analyst rating breakdown for IRMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IRadimed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 02, 2024 | Jason Wittes | Roth Capital | $60.00 | $46.15 | 30.01% | 21.56% |
| Jun 17, 2024 | Frank Takkinen | Loop Capital Markets | $60.00 | $43.28 | 38.62% | 21.56% |
The latest IRadimed stock forecast, released on Aug 02, 2024 by Jason Wittes from Roth Capital, set a price target of $60.00, which represents a 30.01% increase from the stock price at the time of the forecast ($46.15), and a 21.56% increase from IRMD last price ($49.36).
IRadimed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $60.00 |
| Last Closing Price | $49.36 | $49.36 | $49.36 |
| Upside/Downside | -100.00% | -100.00% | 21.56% |
In the current month, the average price target of IRadimed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to IRadimed's last price of $49.36. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 17, 2024 | Lake Street | Buy | Buy | Hold |
IRadimed's last stock rating was published by Lake Street on Jun 17, 2024. The company gave IRMD a "Buy" rating, the same as its previous rate.
IRadimed Financial Forecast
IRadimed Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $17.45M | $16.50M | $16.13M | $15.48M | $14.86M | $13.41M | $12.72M | $12.31M | $11.87M | $10.91M | $9.81M | $9.22M | $8.55M | $7.70M | $6.79M | $8.68M | $10.89M | $9.96M | $9.23M | $8.44M | $7.11M | $5.16M |
| Avg Forecast | $20.96M | $20.55M | $20.01M | $19.13M | $18.94M | $18.15M | $17.65M | $17.15M | $17.30M | $16.18M | $15.66M | $14.77M | $14.90M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $5.86M | $18.59M |
| High Forecast | $21.09M | $20.68M | $20.13M | $19.25M | $19.06M | $18.18M | $17.76M | $17.26M | $17.41M | $16.23M | $15.76M | $14.86M | $14.99M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $7.04M | $22.30M |
| Low Forecast | $20.84M | $20.43M | $19.88M | $19.02M | $18.83M | $18.12M | $17.54M | $17.05M | $17.20M | $16.10M | $15.56M | $14.68M | $14.81M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $4.69M | $14.87M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 1.03% | 1.05% | 1.00% | 1.02% | 1.01% | 1.01% | 1.02% | 1.05% | 1.16% | 1.08% | 1.01% | 0.94% | 1.06% | 0.90% | 1.00% | 1.02% | 1.04% | 1.00% | 1.21% | 0.28% |
IRadimed's average Quarter revenue forecast for Mar 24 based on 1 analysts is $17.15M, with a low forecast of $17.05M, and a high forecast of $17.26M. IRMD's average Quarter revenue forecast represents a -1.73% decrease compared to the company's last Quarter revenue of $17.45M (Dec 23).
IRadimed EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $5.16M | $5.91M | $4.96M | $4.19M | $4.25M | $4.57M | $4.66M | $3.51M | $3.50M | $3.43M | $2.21M | $2.10M | $1.00M | $1.13M | $-2.59M | $1.18M | $2.63M | $2.92M | $2.74M | $1.99M | $1.56M | $-124.79K |
| Avg Forecast | $4.84M | $4.74M | $4.62M | $4.42M | $4.37M | $4.19M | $4.07M | $4.03M | $3.99M | $3.73M | $3.61M | $3.66M | $1.82M | $3.04M | $2.91M | $3.33M | $2.69M | $2.40M | $1.95M | $1.47M | $1.95M | $1.90M | $1.49M | $944.42K | $2.52M | $2.26M | $2.06M | $2.26M | $1.23M | $-449.24K |
| High Forecast | $4.87M | $4.77M | $4.65M | $4.44M | $4.40M | $4.20M | $4.10M | $4.83M | $4.02M | $3.74M | $3.64M | $4.39M | $2.18M | $3.04M | $2.91M | $3.99M | $2.69M | $2.40M | $1.95M | $1.77M | $1.95M | $1.90M | $1.49M | $1.13M | $2.52M | $2.26M | $2.06M | $2.71M | $1.47M | $-359.39K |
| Low Forecast | $4.81M | $4.72M | $4.59M | $4.39M | $4.35M | $4.18M | $4.05M | $3.22M | $3.97M | $3.72M | $3.59M | $2.93M | $1.45M | $3.04M | $2.91M | $2.66M | $2.69M | $2.40M | $1.95M | $1.18M | $1.95M | $1.90M | $1.49M | $755.53K | $2.52M | $2.26M | $2.06M | $1.81M | $980.21K | $-539.08K |
| Surprise % | - | - | - | - | - | - | - | - | 1.29% | 1.58% | 1.37% | 1.14% | 2.34% | 1.50% | 1.60% | 1.05% | 1.30% | 1.43% | 1.13% | 1.43% | 0.52% | 0.59% | -1.74% | 1.25% | 1.05% | 1.29% | 1.33% | 0.88% | 1.27% | 0.28% |
1 analysts predict IRMD's average Quarter EBITDA for Mar 24 to be $4.03M, with a high of $4.83M and a low of $3.22M. This is -21.97% lower than IRadimed's previous annual EBITDA (Dec 23) of $5.16M.
IRadimed Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $4.54M | $5.07M | $4.18M | $3.41M | $3.67M | $3.43M | $3.24M | $2.49M | $3.89M | $2.58M | $1.47M | $1.39M | $637.41K | $1.07M | $-2.11M | $1.77M | $3.24M | $2.45M | $2.09M | $1.85M | $841.20K | $-233.34K |
| Avg Forecast | $5.81M | $5.75M | $5.56M | $5.24M | $5.56M | $5.18M | $4.66M | $2.87M | $4.86M | $4.64M | $3.96M | $2.61M | $2.02M | $3.13M | $3.00M | $2.37M | $2.49M | $2.17M | $1.21M | $970.79K | $1.34M | $1.28M | $-63.79K | $1.42M | $2.62M | $1.98M | $1.91M | $2.09M | $662.76K | $-840.02K |
| High Forecast | $5.86M | $5.80M | $5.60M | $5.28M | $5.60M | $5.30M | $4.70M | $3.44M | $4.99M | $4.77M | $3.99M | $3.13M | $2.42M | $3.13M | $3.00M | $2.84M | $2.49M | $2.17M | $1.21M | $1.16M | $1.34M | $1.28M | $-63.79K | $1.70M | $2.62M | $1.98M | $1.91M | $2.51M | $795.31K | $-672.02K |
| Low Forecast | $5.77M | $5.70M | $5.51M | $5.20M | $5.51M | $5.05M | $4.63M | $2.29M | $4.59M | $4.61M | $3.93M | $2.08M | $1.61M | $3.13M | $3.00M | $1.89M | $2.49M | $2.17M | $1.21M | $776.63K | $1.34M | $1.28M | $-63.79K | $1.13M | $2.62M | $1.98M | $1.91M | $1.67M | $530.21K | $-1.01M |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 1.09% | 1.06% | 1.31% | 1.82% | 1.10% | 1.08% | 1.05% | 1.56% | 1.19% | 1.21% | 1.43% | 0.48% | 0.84% | 33.11% | 1.25% | 1.24% | 1.24% | 1.09% | 0.88% | 1.27% | 0.28% |
IRadimed's average Quarter net income forecast for Mar 24 is $2.87M, with a range of $2.29M to $3.44M. IRMD's average Quarter net income forecast represents a -36.88% decrease compared to the company's last Quarter net income of $4.54M (Dec 23).
IRadimed SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $7.60M | $6.48M | $6.26M | $6.92M | $6.36M | $5.92M | $5.31M | $5.79M | $5.65M | $4.84M | $5.03M | $4.81M | $5.28M | $4.48M | $7.38M | $5.30M | $5.53M | $4.91M | $4.66M | $4.52M | $3.95M | $3.47M |
| Avg Forecast | $10.72M | $10.51M | $10.23M | $9.78M | $9.69M | $9.28M | $9.03M | $6.67M | $8.85M | $8.27M | $8.01M | $6.06M | $2.93M | $6.74M | $6.44M | $5.51M | $5.96M | $5.32M | $4.33M | $3.37M | $4.32M | $4.20M | $3.29M | $4.24M | $5.58M | $5.00M | $4.56M | $5.13M | $3.11M | $12.50M |
| High Forecast | $10.79M | $10.58M | $10.29M | $9.84M | $9.75M | $9.30M | $9.08M | $8.00M | $8.90M | $8.30M | $8.06M | $7.27M | $3.51M | $6.74M | $6.44M | $6.61M | $5.96M | $5.32M | $4.33M | $4.04M | $4.32M | $4.20M | $3.29M | $5.08M | $5.58M | $5.00M | $4.56M | $6.15M | $3.73M | $15.00M |
| Low Forecast | $10.66M | $10.45M | $10.17M | $9.73M | $9.63M | $9.27M | $8.97M | $5.33M | $8.79M | $8.24M | $7.96M | $4.85M | $2.34M | $6.74M | $6.44M | $4.41M | $5.96M | $5.32M | $4.33M | $2.69M | $4.32M | $4.20M | $3.29M | $3.39M | $5.58M | $5.00M | $4.56M | $4.10M | $2.49M | $10.00M |
| Surprise % | - | - | - | - | - | - | - | - | 0.86% | 0.78% | 0.78% | 1.14% | 2.17% | 0.88% | 0.82% | 1.05% | 0.95% | 0.91% | 1.16% | 1.43% | 1.22% | 1.07% | 2.24% | 1.25% | 0.99% | 0.98% | 1.02% | 0.88% | 1.27% | 0.28% |
IRadimed's average Quarter SG&A projection for Mar 24 is $6.67M, based on 1 Wall Street analysts, with a range of $5.33M to $8.00M. The forecast indicates a -12.31% fall compared to IRMD last annual SG&A of $7.60M (Dec 23).
IRadimed EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| EPS | - | - | - | - | - | - | - | - | $0.36 | $0.40 | $0.33 | $0.27 | $0.29 | $0.27 | $0.26 | $0.20 | $0.31 | $0.21 | $0.12 | $0.11 | $0.05 | $0.09 | $-0.17 | $0.15 | $0.28 | $0.22 | $0.19 | $0.17 | $0.08 | $-0.02 |
| Avg Forecast | $0.46 | $0.45 | $0.43 | $0.41 | $0.43 | $0.41 | $0.36 | $0.34 | $0.38 | $0.36 | $0.31 | $0.28 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.05 | $0.04 |
| High Forecast | $0.46 | $0.45 | $0.44 | $0.41 | $0.44 | $0.41 | $0.37 | $0.34 | $0.39 | $0.37 | $0.31 | $0.29 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.06 | $0.04 |
| Low Forecast | $0.45 | $0.45 | $0.43 | $0.41 | $0.43 | $0.40 | $0.36 | $0.33 | $0.36 | $0.36 | $0.31 | $0.28 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.04 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | 0.95% | 1.10% | 1.06% | 0.95% | 0.97% | 1.10% | 1.11% | 0.95% | 1.59% | 1.24% | 1.26% | 1.10% | 0.48% | 0.90% | 34.00% | 1.00% | 1.37% | 1.42% | 1.27% | 1.31% | 1.60% | -0.50% |
According to 1 Wall Street analysts, IRadimed's projected average Quarter EPS for Mar 24 is $0.34, with a low estimate of $0.33 and a high estimate of $0.34. This represents a -6.94% decrease compared to IRMD previous annual EPS of $0.36 (Dec 23).
IRadimed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SGHT | Sight Sciences | $4.66 | $10.25 | 119.96% | Hold |
| NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
| OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
| LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
| LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
| KIDS | OrthoPediatrics | $28.74 | $39.60 | 37.79% | Buy |
| CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
| IRMD | IRadimed | $49.36 | $60.00 | 21.56% | Buy |
| ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
| SRDX | Surmodics | $37.57 | $39.50 | 5.14% | Buy |
| GKOS | Glaukos | $131.38 | $119.33 | -9.17% | Buy |
IRMD Forecast FAQ
Is IRadimed a good buy?
Yes, according to 1 Wall Street analysts, IRadimed (IRMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of IRMD's total ratings.
What is IRMD's price target?
IRadimed (IRMD) average price target is $60 with a range of $60 to $60, implying a 21.56% from its last price of $49.36. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will IRadimed stock go up soon?
According to Wall Street analysts' prediction for IRMD stock, the company can go up by 21.56% (from the last price of $49.36 to the average price target of $60), up by 21.56% based on the highest stock price target, and up by 21.56% based on the lowest stock price target.
Can IRadimed stock reach $70?
IRMD's average twelve months analyst stock price target of $60 does not support the claim that IRadimed can reach $70 in the near future.
What are IRadimed's analysts' financial forecasts?
IRadimed's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $71.89M (high $72.25M, low $71.54M), average EBITDA is $16.66M (high $17.53M, low $15.8M), average net income is $18.26M (high $19.05M, low $17.48M), average SG&A $34.66M (high $36.13M, low $33.2M), and average EPS is $1.54 (high $1.56, low $1.52). IRMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $80.66M (high $81.15M, low $80.17M), average EBITDA is $18.62M (high $18.73M, low $18.5M), average net income is $22.36M (high $22.54M, low $22.19M), average SG&A $41.25M (high $41.5M, low $41M), and average EPS is $1.75 (high $1.76, low $1.74).
Did the IRMD's actual financial results beat the analysts' financial forecasts?
Based on IRadimed's last annual report (Dec 2023), the company's revenue was $65.56M, beating the average analysts forecast of $63.9M by 2.60%. Apple's EBITDA was $20.04M, beating the average prediction of $15M by 33.57%. The company's net income was $17.19M, beating the average estimation of $16.07M by 7.02%. Apple's SG&A was $27.26M, missing the average forecast of $31.19M by -12.58%. Lastly, the company's EPS was $1.35, beating the average prediction of $1.34 by 1.00%. In terms of the last quarterly report (Dec 2023), IRadimed's revenue was $17.45M, beating the average analysts' forecast of $17.3M by 0.88%. The company's EBITDA was $5.16M, beating the average prediction of $3.99M by 29.23%. IRadimed's net income was $4.54M, missing the average estimation of $4.86M by -6.51%. The company's SG&A was $7.6M, missing the average forecast of $8.85M by -14.07%. Lastly, the company's EPS was $0.36, missing the average prediction of $0.38 by -5.26%